Article Figures & Data
Figures
- Figure 1 AQP4-IgG (binding and complement-mediated cell killing) titers of specimens drawn at different time points (remission, preattack, and attack) in individual patients (original titer values shown in transformed scale)
(A.a) AQP4-IgG titers grouped into preattack, attack, and remission categories. (B.a) AQP4-IgG titers categorized according to baseline immunotherapy*. (C.a) AQP4-IgG titers categorized by attack severity type**. (A.b) AQP4 complement-mediated cell killing titers grouped into preattack, attack, and remission categories. (B.b) AQP4 complement-mediated cell killing titers categorized according to baseline immunotherapy*. (C.b) AQP4 complement-mediated cell killing titers categorized grouped into attack severity type**. *Immunotherapy included azathioprine, mycophenolate mofetil, cyclophosphamide, and rituximab. **Definition in the supplement. AQP4 = aquaporin-4; IgG = immunoglobulin G; IST = immunosuppressive therapy.
- Figure 2 Kaplan-Meier estimates of time to develop EDSS score ≥ 6
Years from the first aquaporin-4–immunoglobulin G complement-mediated cell killing titers to develop EDSS score ≥6. All Martinique patients, any patients with unknown status for each outcome, and any patients with missing complement values were excluded from the corresponding analysis. EDSS = Expanded Disability Status Scale.
- Figure 3 Correlation between M23-AQP4 end titer and M23-AQP4 complement-mediated cell killing titers
AQP4 = aquaporin-4; IgG = immunoglobulin G.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.